Journal September 26, 2026 5 min read

Which peptides are studied in relation to prolactin?

A research-supply overview of peptide and peptide-adjacent compounds examined in prolactin-related laboratory and clinical literature, including GnRH agonists, amylin analogues, and adipokines.

peptides-pro Editorial

The peptides most frequently examined in relation to prolactin in the supplied evidence are gonadotropin-releasing hormone (GnRH) agonists, particularly goserelin and leuprolide, which are studied for their effects on gonadal steroidogenesis and, indirectly, prolactin regulation. Other compounds include amylin receptor agonists such as cagrilintide, the adipokine asprosin, and various growth hormone–releasing peptides (GHRH analogues and growth hormone secretagogues) that may influence prolactin through hypothalamic–pituitary pathways. Prolactin itself is a 199-amino-acid polypeptide hormone (molecular weight ~23 kDa) secreted by lactotroph cells of the anterior pituitary; it is not a research peptide supplied for laboratory use but is measured as an endocrine biomarker in studies of these compounds.

The work centres on the hypothalamic–pituitary–gonadal (HPG) axis and the dopamine D2 receptor–mediated tonic inhibition of prolactin secretion, with additional input from the GH–IGF-1 axis and amylin receptor signalling in the caudal brainstem.

Research Studies

Goserelin and leuprolide in premenopausal breast cancer: effects on ovarian suppression and prolactin

Goserelin and leuprolide are GnRH agonists used for ovarian function suppression in premenopausal breast cancer patients receiving adjuvant endocrine therapy. A retrospective cohort study compared their efficacy and safety, noting that different molecular structures may lead to clinically meaningful differences [12]. While prolactin was not the primary endpoint, GnRH agonist–induced oestrogen suppression can indirectly affect prolactin levels, as oestrogen stimulates lactotroph proliferation and prolactin secretion. The study population was premenopausal women with breast cancer; no direct prolactin data were reported in the supplied evidence.

Cagrilintide and amylin receptor signalling in the dorsal vagal complex

Cagrilintide is a long-acting amylin receptor agonist under investigation for obesity. A cross-species atlas of the dorsal vagal complex (DVC) in rat, mouse, and macaque revealed that cagrilintide regulates two conserved Calcr-expressing neuronal populations [4]. Acute treatment altered gene expression in area postrema Calcr/Ramp3 neurons, while long-term treatment upregulated specific transcripts. Although prolactin was not measured, amylin receptors are expressed in the hypothalamus and may modulate prolactin release via central pathways. The evidence is animal-only (rat, mouse, macaque) and does not directly address prolactin.

Asprosin and SSRI-induced male dysfunction in rats

Asprosin is a fasting-induced adipokine that crosses the blood–brain barrier and activates orexigenic agouti-related peptide neurons. In SSRI-treated rats, asprosin infusion restored erectile function, copulatory behaviour, and testicular morphology [5]. Prolactin is known to influence sexual function, and SSRI-induced hyperprolactinaemia is a recognised side effect; however, the study did not report prolactin levels. The findings are animal-only and do not establish a prolactin-mediated mechanism.

GHRH analogues and growth hormone secretagogues: potential prolactin interactions

Performance-enhancing peptides marketed as research compounds include GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without DAC) and growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), as well as the GH fragment AOD9604 and IGF-1 analogues [3]. These agents modulate the GH–IGF-1 axis, which intersects with prolactin regulation at the hypothalamic level; GHRP-2 and GHRP-6 have been shown to stimulate prolactin secretion in some clinical studies, though the supplied evidence does not provide specific prolactin data. The context is self-administration and clinical practice, not controlled research on prolactin.

Prolactin as a biomarker in a blackcurrant-based supplement trial

A registered clinical trial (NCT07166835) investigating a blackcurrant-based nootropic drink under normobaric hypoxia lists prolactin among its biomarkers, alongside MAO-B, BDNF, hsCRP, S100B, C3G, and sarmentosin [7]. The study is a double-blind, randomised, placebo-controlled crossover in healthy participants; prolactin is measured but not the primary outcome. No results are available.

Peptides and prolactin in migraine pathophysiology

A clinical trial protocol on cytokines and regulatory T lymphocytes in migraine mentions several peptides, including calcitonin gene-related peptide (CGRP), and notes that prolactin may be involved in migraine pathophysiology [8]. The study population includes patients with autoimmune and inflammatory diseases. Prolactin is not a primary focus, and no data are reported.

Pituitary pathology and prolactin: abscess, metastasis, and hypophysitis

Case reports and series describe pituitary lesions that can disrupt prolactin regulation. A case report of pituitary abscess with POEMS-like syndrome noted panhypopituitarism as a potential outcome [1]. A retrospective series of pituitary metastasis characterised endocrine phenotypes, including prolactin abnormalities, in 14 patients [2]. A systematic review of hypophysitis in sarcoidosis described endocrine dysfunction, which may include hyperprolactinaemia [11]. These are clinical observations, not studies of peptide administration.

Probiotics and hormone metabolism in overweight women

A randomised, double-blind, placebo-controlled trial examined the effects of Lacticaseibacillus rhamnosus LRa05, Limosilactobacillus reuteri LR08, and Lactobacillus crispatus LCr86 on hormone metabolism, body composition, and emotional regulation in overweight women [9]. Prolactin was among the hormones assessed, though the supplied evidence does not report specific prolactin results. The intervention is not a peptide but a probiotic formulation.

Photoperiodic plasticity and prolactin in seasonal breeders

Transcriptomic analyses of limbic structures in Siberian hamsters and Japanese quail across photoperiodic phenotypes identified seasonal changes in gene expression [10]. Prolactin is a key mediator of seasonal reproduction in these species, but the supplied evidence does not detail prolactin-specific findings. The work is animal-only and does not involve exogenous peptides.

If you are reading this for personal health reasons

The compounds discussed here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.